Related Experiment Video
Updated: Jun 22, 2026

06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
[Tadenan treatment of prostatic adenoma]
Urologiia (Moscow, Russia : 1999)
|June 17, 2009
Abstract:
Tadenan, a drug of plant origin, was given to 27 patients with documented prostatic adenoma for 3-12 months. Home uroflowmonitoring for 1, 3, 6 and 12 months registered positive changes in urinary flow rate and urination volume. Side effects were absent. IPSS and QoL parameters were also assessed.
